Welcome to our dedicated page for Phibro Animal news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal stock.
Phibro Animal Health Corporation (Nasdaq: PAHC) is a diversified global animal health and nutrition company with operations across Animal Health, Mineral Nutrition, and Performance Products. This news page aggregates company-issued updates and other coverage related to PAHC stock, helping readers follow developments that Phibro discloses through press releases and regulatory communications.
Phibro’s news flow frequently includes financial results and guidance, such as quarterly and full-year earnings releases and updates to financial outlook for future fiscal years. These announcements often detail net sales by segment, trends in medicated feed additives (MFAs), nutritional specialty products, vaccines, mineral nutrition products, and performance products, as well as commentary on factors like product demand, foreign currency impacts, and operating expenses.
Investors can also expect corporate and strategic announcements, including information about acquisitions or portfolio additions, such as the referenced MFA portfolio acquired from Zoetis, Inc., and enterprise programs like Phibro Forward, which the company describes as focused on efficiency, growth, and cultural engagement. Leadership and governance updates, including planned executive transitions and matters presented at the annual meeting of stockholders, are typically communicated through press releases and accompanying SEC filings.
Product and pipeline-related news is another key category. Phibro has highlighted developments in companion animal oral health, including the licensing agreement with Lighthouse Pharmaceuticals, Inc. for a proprietary compound for canine periodontal care and the national launch of Restoris piezoelectric dental gel for dogs with periodontal disease. Such releases describe product mechanisms, study results, and distribution plans.
In addition, Phibro issues dividend declarations, notices of participation in investor conferences, and details on upcoming webcasts and conference calls to discuss results. Readers interested in PAHC can use this page to monitor these recurring updates and review the company’s own descriptions of its performance, strategy, and product initiatives.
Summary not available.
Summary not available.
Phibro Animal Health Corporation (NASDAQ: PAHC) is set to announce its third quarter financial results on May 3, 2023, after market close. A conference call will follow on May 4, 2023, at 9:00 AM ET, accessible via phone or webcast. Interested parties can find the webcast on the company's investor relations page. Phibro aims to provide solutions for animal health and nutrition, enhancing the well-being of livestock and companion animals. More details about the results will be made available during the call, along with insights into the company's performance and future outlook.
Phibro Animal Health Corporation (NASDAQ: PAHC) will participate in the Bank of America Securities 2023 Health Care Conference on May 9, 2023, at 4:20 PM PDT. Chief Financial Officer Damian Finio will present to financial analysts and investors. The live audio presentation can be accessed on the company’s Investor Relations website, with a replay and archived session available thereafter.
Phibro is a global leader in animal health and mineral nutrition, dedicated to supporting livestock producers, veterinarians, and consumers in enhancing animal health. For more information, visit www.pahc.com.
Phibro Animal Health Corporation (NASDAQ: PAHC) will participate in the Barclays Global Healthcare Conference on March 15, 2023, at 10:45 AM ET. CFO Damian Finio will present to financial analysts and investors at the Loews Miami Beach Hotel. A live audio presentation will be available on the company's Investor Relations Website, with a replay to follow. Phibro is recognized as a leader in animal health and mineral nutrition, supporting livestock producers and veterinarians in enhancing animal wellbeing.
Phibro Animal Health Corporation (NASDAQ:PAHC) will participate in the Bank of America 2023 Virtual Animal Health Summit on Thursday, March 2, 2023, at 10:50 AM ET. Chief Financial Officer Damian Finio and Executive Vice President, Corporate Strategy Daniel Bendheim will address financial analysts and investors during this event. The live audio presentation can be accessed on the company's Investor Relations Website, with a replay available afterwards. Phibro is a global leader in animal health and mineral nutrition, dedicated to enhancing the health of farm and companion animals.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported its second-quarter financial results for the period ending December 31, 2022. Net sales increased 5% to $244.6 million, while net income fell 59% to $7.2 million, resulting in diluted EPS of $0.18. Adjusted EBITDA rose 6% to $30.9 million. The Animal Health segment saw a 9% sales increase, offset by an 8% decline in Mineral Nutrition. SG&A expenses surged 27% due to environmental remediation costs. The company updated its FY2023 guidance, lowering net income and diluted EPS forecasts but maintaining sales and adjusted EBITDA projections.
Phibro Animal Health Corporation (NASDAQ: PAHC) has appointed Alejandro Bernal as a Class III director, effective immediately, increasing the Board membership to nine, with six independent directors. Bernal, CEO of PetDx and former President of Mars Veterinary Health, brings extensive experience in the animal health sector. Additionally, the Board declared a quarterly cash dividend of $0.12 per share on Class A and Class B common stock, payable on March 22, 2023, to shareholders of record by March 1, 2023.
Phibro Animal Health Corporation (NASDAQ: PAHC) will report its second quarter financial results on February 8, 2023, following the market's close. A conference call will be held on February 9, 2023, at 9:00 AM ET, giving interested parties access via a live webcast or by calling in. This provides an opportunity for investors to gain insights into the company's financial health and future outlook. For more details, visit Phibro's investor relations page.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported its financial results for Q1 2023, ending September 30, 2022. Net sales reached $232.5 million, an 8% increase year-over-year, driven mainly by Animal Health and Mineral Nutrition segments. However, net income fell 41% to $3.9 million, with diluted EPS dropping to $0.10. Adjusted EBITDA slightly declined to $22.1 million. The company reiterated guidance for net sales but revised forecasts for net income and EPS, reflecting increased interest rates and changes in tax legislation.
FAQ
What is the current stock price of Phibro Animal (PAHC)?
What is the market cap of Phibro Animal (PAHC)?
